Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:53:28 2024-03-28 pm EDT 5-day change 1st Jan Change
40.71 USD -0.05% Intraday chart for Halozyme Therapeutics, Inc. +1.02% +9.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing MT
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating MT
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance MT
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021. CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83 MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares. CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024 CI
Halozyme Therapeutics, Inc. authorizes a Buyback Plan. CI
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy CI
Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing MT
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients MT
Goldman Sachs Cuts Halozyme Therapeutics' Price Target to $40 From $45, Keeps Neutral Rating MT
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis CI
HC Wainwright Cuts Halozyme Therapeutics Price Target to $48 From $61, Maintains Buy Rating MT
Transcript : Halozyme Therapeutics, Inc. - Special Call
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023 CI
Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC MT
Takeda Pharmaceutical Says US FDA Approves Hyqvia as Neuromuscular Disorder Maintenance Therapy MT
Chart Halozyme Therapeutics, Inc.
More charts
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
40.73 USD
Average target price
50.7 USD
Spread / Average Target
+24.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Halozyme Therapeutics, Inc. - Nasdaq
  4. News Halozyme Therapeutics, Inc.
  5. Halozyme Therapeutics Q4 Adjusted EPS, Revenue Decline; FY2022 Guidance Reiterated